JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

Search

Cartesian Therapeutics Inc

Suletud

7.23 -1.36

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.09

Max

7.41

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+359.92% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. märts 2026

Cartesian Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. jaan 2026, 23:07 UTC

Tulu

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27. jaan 2026, 21:27 UTC

Tulu

Texas Instruments 4Q Sales Rise, Profit Falls

27. jaan 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27. jaan 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. jaan 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27. jaan 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27. jaan 2026, 23:20 UTC

Tulu

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27. jaan 2026, 23:20 UTC

Tulu

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27. jaan 2026, 23:19 UTC

Tulu

SK Innovation Posts Net Loss for Second Consecutive Year

27. jaan 2026, 23:19 UTC

Tulu

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27. jaan 2026, 23:18 UTC

Tulu

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27. jaan 2026, 23:18 UTC

Tulu

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27. jaan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27. jaan 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27. jaan 2026, 23:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27. jaan 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27. jaan 2026, 22:06 UTC

Tulu

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27. jaan 2026, 21:51 UTC

Tulu

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. jaan 2026, 21:43 UTC

Tulu

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27. jaan 2026, 21:41 UTC

Tulu

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27. jaan 2026, 21:38 UTC

Tulu

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27. jaan 2026, 21:32 UTC

Tulu

Ampol: Modest Profit From F&I International in 2025

27. jaan 2026, 21:32 UTC

Tulu

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27. jaan 2026, 21:31 UTC

Tulu

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27. jaan 2026, 21:31 UTC

Tulu

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27. jaan 2026, 21:30 UTC

Tulu

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27. jaan 2026, 21:29 UTC

Tulu

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27. jaan 2026, 21:29 UTC

Tulu

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27. jaan 2026, 21:28 UTC

Tulu

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Võrdlus sarnastega

Hinnamuutus

Cartesian Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

359.92% tõus

12 kuu keskmine prognoos

Keskmine 35 USD  359.92%

Kõrge 44 USD

Madal 16 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Cartesian Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

6

Osta

2

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat